Green Cross Corp
KRX:006280

Watchlist Manager
Green Cross Corp Logo
Green Cross Corp
KRX:006280
Watchlist
Price: 170 200 KRW 2.1% Market Closed
Market Cap: 1.9T KRW
Have any thoughts about
Green Cross Corp?
Write Note

Green Cross Corp
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Green Cross Corp
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Green Cross Corp
KRX:006280
Income from Continuing Operations
-â‚©22.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Income from Continuing Operations
â‚©183.8B
CAGR 3-Years
-31%
CAGR 5-Years
-5%
CAGR 10-Years
6%
SK Bioscience Co Ltd
KRX:302440
Income from Continuing Operations
â‚©22.3B
CAGR 3-Years
-12%
CAGR 5-Years
20%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Income from Continuing Operations
â‚©119.4B
CAGR 3-Years
20%
CAGR 5-Years
17%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Income from Continuing Operations
â‚©88.1B
CAGR 3-Years
22%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Income from Continuing Operations
-â‚©5.1B
CAGR 3-Years
41%
CAGR 5-Years
11%
CAGR 10-Years
N/A
No Stocks Found

Green Cross Corp
Glance View

Market Cap
1.9T KRW
Industry
Biotechnology

Green Cross Corporation, rooted in South Korea, has built a formidable presence in the biopharmaceutical industry, primarily focusing on the development and commercialization of vaccines, plasma-derived products, and therapeutic proteins. Founded in 1967, the company initially garnered attention for its innovative efforts in producing hepatitis B vaccines. Over the years, Green Cross expanded its repertoire to include a wide array of biologics. Its operations are vertically integrated, encompassing everything from initial research and development to production and marketing. The company leverages its advanced manufacturing facilities and cutting-edge technology to maintain stringent quality standards and competitive pricing—a strategy that has allowed it to grow both domestically and internationally. A crucial revenue stream for Green Cross arises from its plasma derivatives segment, where the collection and processing of human plasma form the backbone of multiple high-demand medical products, including immunoglobulins, albumin, and clotting factors. Green Cross also benefits from partnerships and collaborations that extend its global footprint, fostering innovation through shared resources and knowledge. Export-driven sales further bolster revenue, as the company taps into growing healthcare needs across various markets around the globe. In essence, Green Cross capitalizes on a meticulous blend of research innovation, quality control, and strategic market expansion, solidifying its role as a key player in the global biopharmaceutical landscape.

Intrinsic Value
216 615.19 KRW
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Green Cross Corp's Income from Continuing Operations?
Income from Continuing Operations
-22.5B KRW

Based on the financial report for Sep 30, 2024, Green Cross Corp's Income from Continuing Operations amounts to -22.5B KRW.

What is Green Cross Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 1Y
-632%

Over the last year, the Income from Continuing Operations growth was -632%.

Back to Top